The median OS of approximately 3 months for male patients among all mutSMARCA4 patients and among the NCSLC subgroup, compared to the median OS of female patients of approximately 43 months among all mutSMARCA4 patients and un-estimable among the NSCLC subgroup, suggests that the poor prognosis associated with SMARCA4-mutated malignancies was primarily driven by the poor prognosis of male patients. Here, SMARCA4 is linked to non-small cell lung carcinoma.